<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287816</url>
  </required_header>
  <id_info>
    <org_study_id>2019H0504-A</org_study_id>
    <nct_id>NCT04287816</nct_id>
  </id_info>
  <brief_title>Achieving Nutritional Adequacy Of Vitamins E and K With An Egg/Plant-Based Food Pairing - Study 1</brief_title>
  <official_title>Achieving Nutritional Adequacy Of Vitamins E and K With An Egg/Plant-Based Food Pairing - Study 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malnutrition of the fat-soluble nutrients vitamin E (α-tocopherol; αT) and vitamin K&#xD;
      (phylloquinone; PQ) is problematic. Since αT and PQ are rich in plant foods (e.g. spinach)&#xD;
      that are mostly absent of accessible lipid, dietary patterns that can potentiate αT and PQ&#xD;
      bioavailability by pairing vegetables with lipid-rich foods have been emphasized. The purpose&#xD;
      of this study is to use deuterium-labeled spinach (containing stable isotopes of αT and PQ)&#xD;
      to validate eggs as a dietary tool to improve αT and PQ bioavailability directly from a model&#xD;
      plant food, and hence achieve nutrient adequacy. It is expected that compared with&#xD;
      deuterium-labeled spinach alone, co-ingestion of eggs will dose- and time-dependently&#xD;
      increase plasma bioavailability of spinach-derived deuterium-labeled αT and PQ without&#xD;
      affecting time to maximal concentrations or half-lives. The outcome will therefore support an&#xD;
      egg-based food pairing that can enhance the health benefits of plant-centric dietary&#xD;
      patterns.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the US, 92-96% and 43-63% of men and women do not meet recommended intakes for αT and PQ,&#xD;
      respectively. Dietary recommendations strongly encourage a diet rich in fruits and vegetables&#xD;
      to meet dietary αT and PQ requirements. However, αT and PQ bioavailability from most plant&#xD;
      foods is quite poor, thereby emphasizing a need for effective food pairings that can enhance&#xD;
      the absorption and promote adequate status of these health-promoting nutrients. The objective&#xD;
      of this application is to use deuterium-labeled spinach (containing stable isotopes of αT and&#xD;
      PQ) to validate eggs as a dietary tool to improve αT and PQ bioavailability directly from a&#xD;
      model plant food, and hence achieve nutrient adequacy. Our hypothesis is that the&#xD;
      bioavailability of αT and PQ from deuterium-labeled spinach will be potentiated by egg intake&#xD;
      in a dose-dependent manner by increasing their secretion in intestinal-derived chylomicrons.&#xD;
&#xD;
      To test this, our specific aim is to assess egg-mediated improvements in αT and PQ&#xD;
      bioavailability by conducting a randomized cross-over pharmacokinetic study in healthy men&#xD;
      and women. In Study Arms 1-4, participants will ingest deuterium-labeled spinach (containing&#xD;
      2 mg αT and 500 μg PQ) with 0, 1, 2, or 3 hardboiled eggs (containing 0, 4.8, 9.6, or 14.4 g&#xD;
      total fat, respectively). In Study Arm 5, participants will ingest spinach alone followed by&#xD;
      1 egg 3-hours later. In Study Arm 6, participants will ingest spinach with 1 egg followed by&#xD;
      another egg 3-hours later. Thus, Study Arms 1-4 will test the dose-dependent effects of eggs&#xD;
      on nutrient bioavailability and Study Arms 5-6 (with comparison to Study Arms 1 and 2) will&#xD;
      test the 'timing'-dependent effects of eggs on nutrient bioavailability. Eucaloric diets will&#xD;
      be controlled for αT and PQ intakes for 3 d prior to and during the initial 24 h of each&#xD;
      trial to minimize heterogeneity of pharmacokinetic responses. Spinach-derived&#xD;
      deuterium-labeled αT and PQ will be measured in plasma and isolated chylomicrons collected at&#xD;
      timed intervals from 0-72 h post-meal ingestion, and biomarkers of antioxidant status and&#xD;
      oxidative distress will be assessed at baseline (0 h) of each trial. Outcomes from this study&#xD;
      are expected to demonstrate a dose- and time-dependent function of eggs to increase&#xD;
      deuterium-labeled αT and PQ bioavailability (based on AUC0-72 h, Cmax, and % estimated&#xD;
      absorption).&#xD;
&#xD;
      The rationale for this study is that, by establishing the efficacy of eggs to potentiate&#xD;
      plant-derived fat-soluble nutrient bioavailability, a strong framework will exist for an&#xD;
      easily implementable health-promoting food pairing strategy to overcome malnutrition of αT&#xD;
      and PQ.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin E Bioavailability</measure>
    <time_frame>0, 3, 4.5, 6, 7.5, 9, 12, 24, 36, 48, 72 hours post-ingestion of spinach</time_frame>
    <description>Area under the curve of deuterium-labeled alpha-tocopherol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin E Cmax</measure>
    <time_frame>0-72 hours post-ingestion of spinach</time_frame>
    <description>Maximum plasma concentration of deuterium-labeled alpha-tocopherol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated Absorption (%Dose) of Vitamin E</measure>
    <time_frame>0-72 hours post-ingestion of spinach</time_frame>
    <description>Absorption of deuterium-labeled alpha-tocopherol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin K Bioavailability</measure>
    <time_frame>0, 3, 4.5, 6, 7.5, 9, 12, 24, 36, 48, 72 hours post-ingestion of spinach</time_frame>
    <description>Area under the curve of deuterium-labeled phylloquinone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin K Cmax</measure>
    <time_frame>0-72 hours post-ingestion of spinach</time_frame>
    <description>Maximum plasma concentration of deuterium-labeled phylloquinone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated Absorption (%Dose) of Vitamin K</measure>
    <time_frame>0-72 hours post-ingestion of spinach</time_frame>
    <description>Absorption of deuterium-labeled phylloquinone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vitamin E Tmax</measure>
    <time_frame>0-72 hours post-ingestion of spinach</time_frame>
    <description>Time to reach maximum plasma concentration of deuterium-labeled alpha-tocopherol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chylomicron Vitamin E</measure>
    <time_frame>0, 3, 4.5, 6, 7.5, 9, 12 hours post-ingestion of spinach</time_frame>
    <description>Deuterium-labeled alpha-tocopherol concentration in chylomicron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate of Vitamin E</measure>
    <time_frame>0-72 hours post-ingestion of spinach</time_frame>
    <description>Rate of plasma elimination of deuterium-labeled alpha-tocopherol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin K Tmax</measure>
    <time_frame>0-72 hours post-ingestion of spinach</time_frame>
    <description>Time to reach maximum plasma concentration of deuterium-labeled phylloquinone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chylomicron Vitamin K</measure>
    <time_frame>0, 3, 4.5, 6, 7.5, 9, 12 hours post-ingestion of spinach</time_frame>
    <description>Deuterium-labeled phylloquinone concentration in chylomicron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate of Vitamin K</measure>
    <time_frame>0-72 hours post-ingestion of spinach</time_frame>
    <description>Rate of plasma elimination of deuterium-labeled phylloquinone</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Vitamin C</measure>
    <time_frame>Prior to (0 hour) spinach consumption</time_frame>
    <description>Baseline plasma vitamin C concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Malondialdehyde</measure>
    <time_frame>Prior to (0 hour) spinach consumption</time_frame>
    <description>Baseline plasma malondialdehyde concentration</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Nutritional Requirements</condition>
  <arm_group>
    <arm_group_label>Zero hard-boiled egg at 0 h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No eggs will be consumed on the test day. Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone prior to the 72-h pharmacokinetics trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One hard-boiled egg at 0 h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 1 hard-boiled egg prior to the 72-h pharmacokinetics trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two hard-boiled eggs at 0 h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 2 hard-boiled eggs prior to the 72-h pharmacokinetics trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Three hard-boiled eggs at 0 h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 3 hard-boiled eggs prior to the 72-h pharmacokinetics trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One hard-boiled egg at 3 h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone at 0 h prior to the 72-h pharmacokinetics trial followed by 1 hard-boiled egg 3 hours after spinach consumption.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One hard-boiled egg at 0 h + One hard-boiled egg at 3 h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 1 hard-boiled egg at 0 h prior to the 72-h pharmacokinetics trial followed by 1 egg 3 hours after spinach consumption.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Zero hard-boiled egg at 0 h</intervention_name>
    <description>No eggs will be consumed on test day along with spinach consumption</description>
    <arm_group_label>Zero hard-boiled egg at 0 h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>One hard-boiled egg at 0 h</intervention_name>
    <description>One egg will be consumed on test day along with spinach consumption</description>
    <arm_group_label>One hard-boiled egg at 0 h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Two hard-boiled eggs at 0 h</intervention_name>
    <description>Two eggs will be consumed on test day along with spinach consumption</description>
    <arm_group_label>Two hard-boiled eggs at 0 h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Three hard-boiled eggs at 0 h</intervention_name>
    <description>Three eggs will be consumed on test day along with spinach consumption</description>
    <arm_group_label>Three hard-boiled eggs at 0 h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>One hard-boiled egg at 3 h</intervention_name>
    <description>One egg will be consumed on test day three hours after spinach consumption</description>
    <arm_group_label>One hard-boiled egg at 3 h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>One hard-boiled egg at 0 h + One hard-boiled egg at 3 h</intervention_name>
    <description>Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption</description>
    <arm_group_label>One hard-boiled egg at 0 h + One hard-boiled egg at 3 h</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) = 19-25 kg/m2&#xD;
&#xD;
          -  Normolipidemic (total cholesterol &lt;240 mg/dL; triglyceride &lt;150 mg/dL)&#xD;
&#xD;
          -  Fasting glucose &lt;100 mg/dL&#xD;
&#xD;
          -  Normal hematocrit level (41%-50% for men and 36%-48% for women)&#xD;
&#xD;
          -  Normal hemoglobin level (13.5-17.5 g/dL for men and 12.0-15.5 g/dL for women)&#xD;
&#xD;
          -  No use of dietary supplements for &gt;1 month&#xD;
&#xD;
          -  No use of medications that affect lipid or glucose metabolism&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
          -  No history of gastrointestinal disorders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Egg allergy&#xD;
&#xD;
          -  Alcohol intake &gt; 2 drinks per day&#xD;
&#xD;
          -  Aerobic activity &gt;7 h/wk&#xD;
&#xD;
          -  Body mass change &gt;2 kg in the past 1 month&#xD;
&#xD;
          -  Women who are pregnant, lactating, or initiated or changed birth control in the past 3&#xD;
             month&#xD;
&#xD;
          -  Vegetarian&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard S Bruno, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard S Bruno, Ph.D.</last_name>
    <phone>614-292-5522</phone>
    <email>bruno.27@osu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Richard S Bruno, Ph.D.</last_name>
      <phone>614-292-5522</phone>
      <email>bruno.27@osu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 22, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Richard Bruno</investigator_full_name>
    <investigator_title>Professor and Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vitamin E</keyword>
  <keyword>Vitamin K</keyword>
  <keyword>Egg</keyword>
  <keyword>Spinach</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombin III</mesh_term>
    <mesh_term>Antithrombins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

